Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
APRI > SEC Filings for APRI > Form 8-K on 1-Apr-2013All Recent SEC Filings

Show all filings for APRICUS BIOSCIENCES, INC. | Request a Trial to NEW EDGAR Online Pro



Entry into a Material Definitive Agreement, Completion of Acquisition o

Item 1.01 Entry into a Material Definitive Agreement.

On March 26, 2013, Apricus Pharmaceuticals USA, Inc., a wholly owned subsidiary of Apricus Biosciences, Inc. (collectively, the "Company"), entered into an Asset Purchase Agreement (the "Agreement") whereby the Company agreed to sell to Biocodex, Inc. (the "Buyer") all of the Company's rights and certain related information, property and inventory related to Totect® (the "Assets") in exchange for $1,500,000 in cash at the closing date plus the right to receive double-digit, tiered, decreasing royalties based on the Buyer's net sales over the next three years (the "Transaction"). The Transaction closed simultaneously with signing the Asset Purchase Agreement. Totect® (dexrazoxane HCl) is a marketed, injectable treatment for anthracycline extravasation.

Pursuant to the Agreement, the Company agreed to indemnify the Buyer against certain claims, including those related to breaches by the Company of any "Material Contract" (as defined in the Agreement) and any activities of the Company relating to the Assets prior to the closing date. Additionally, the Company retained all liabilities arising in connection with the manufacture or commercialization of Totect® by the Company prior to the closing date of the Transaction.

We expect to record a loss on sale of the assets estimated to be approximately $1,300,000 in the quarter ended March 31, 2013. The future royalty amounts received, if any, will be reflected as a recovery on the loss of the sale on assets when earned over the royalty term.

The foregoing summary is qualified in its entirety by reference to the Agreement, which is filed herewith as Exhibit 2.1. Portions of the Agreement are subject to a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted material will be included in the request for confidential treatment.

Item 2.01 Completion of Acquisition or Disposition of Assets.

The disclosure set forth under Item 1.01 is incorporated by reference into this Item 2.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.        Description

2.1*               Asset Purchase Agreement, dated March 26, 2013, by and between
                   Apricus Pharmaceuticals USA, Inc. and Biocodex, Inc.

* Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.

  Add APRI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for APRI - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.